GammaTile
Latest round
- Series E
Last raised
- May 2026
Total raised
- $164M
Investors
- 11
About GammaTile
GT Medical Technologies, Inc. is a US-based company specializing in GammaTile Therapy, an innovative treatment for malignant intracranial neoplasms that reduces radiation exposure to healthy tissue during cancer treatment. Founded in 2017, GT Medical Technologies, Inc. is based in Tempe, US, and focuses on developing advanced solutions in oncology. In June 2026, GT Medical Technologies, Inc. GT Medical Technologies specializes in the development and delivery of GammaTile Therapy, a unique treatment solution for patients diagnosed with malignant intracranial neoplasms. This therapy involves placing GammaTile, a surgically targeted radiation therapy system, during tumor resection by neurosurgeons. GammaTile Therapy aims to minimize radiation exposure to healthy tissue, significantly improving patient outcomes by delaying tumor recurrence and potentially extending survival.GT Medical Technologies generates revenue through direct sales of its GammaTile Therapy product to healthcare facilities, including hospitals and specialized cancer treatment centers. Transactions typically occur through a direct-to-consumer model, allowing healthcare providers to purchase the GammaTile system and associated training services directly from the company. Pricing structures are tailored based on the specific needs of healthcare providers, ensuring effective implementation of GammaTile Therapy within clinical settings. The company will focus on expanding commercial adoption of GammaTile across hospitals and cancer centers while advancing clinical validation through ongoing trials such as BRIDGES for glioblastoma. Continued investment in clinical data generation and regulatory support will strengthen its positioning as a standard-of-care treatment. Scaling manufacturing and operational infrastructure will support wider market penetration, while positive trial outcomes may enable international expansion and new indications in brain tumor treatment.
Who invested in GammaTile
11 investors across 7 rounds
See all investors in GammaTile
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series E
May 8, 2026
Amount
$50M
Investors
Series D
Jun 10, 2025
Amount
$16M
Investors
Series D
Dec 23, 2024
Amount
$37M
Investors
Series C
Mar 20, 2023
Amount
$37M
Investors
Series B
Nov 13, 2020
Amount
$15M
Investors
Series A
Nov 14, 2018
Amount
$5.6M
Investors
Seed
Dec 29, 2017
Amount
$1.9M
Investors
Questions about GammaTile
Who invested in GammaTile?
GammaTile has 11 investors on record across 7 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has GammaTile raised?
GammaTile has raised 7 venture rounds. Sign up free to see how much each round raised and the total.
When did GammaTile last raise money?
GammaTile's most recent round on record is a Series E, in May 2026.
What does GammaTile do?
GammaTile is a medical devices & equipment company.
Where is GammaTile headquartered?
GammaTile is headquartered in Tempe, US.
Which VCs invest in companies like GammaTile?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back medical devices & equipment companies at GammaTile's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series E
Raising like GammaTile? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.